GPCR.NASDAQStructure Therapeutics INC
10-K: Structure Therapeutics Reports Positive 2024 Results, Advances Obesity and IPF Programs
Sentiment:
Annual Report
Structure Therapeutics Inc. announces its 2024 financial results and highlights progress in its clinical programs targeting obesity and idiopathic pulmonary fibrosis (IPF).
Delay expectedTopline data from the obesity cohort of the Phase 2a trial of aleniglipron was delayed due to a data collection omission by a clinical site.
Summary
- Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for chronic diseases.
- The company's lead product candidate, aleniglipron, is in Phase 2 clinical trials for obesity and related conditions, with positive topline data reported, including a 6.2% placebo-adjusted mean weight decrease at 12 weeks.
- A new tablet formulation of aleniglipron demonstrated a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks.
- The company initiated Phase 2b studies (ACCESS and ACCESS II) of aleniglipron in Q4 2024, with topline data expected in Q4 2025.
- ACCG-2671, an oral small molecule amylin receptor agonist, is in IND-enabling studies, with Phase 1 clinical trials expected to begin in Q4 2025.
- ANPA-0073, an oral small molecule APJ receptor agonist, is Phase 2 ready and being evaluated for muscle-sparing weight loss.
- LTSE-2578, an oral small molecule LPA1R antagonist for IPF, is in a Phase 1 clinical study, with initial data expected in 2025.
- The company's technology platform combines structure-based drug discovery and computational chemistry to target GPCRs.
- The company has collaborations with Schrdinger, LLC for drug discovery and development.
- The company reported net losses of $122.5 million for 2024 and $89.6 million for 2023.
- As of December 31, 2024, the company had cash, cash equivalents, and short-term investments of $883.5 million, expected to fund operations through at least 2027.
- The company has 163 full-time employees as of December 31, 2024.
Sentiment
Score: 7
Explanation: The document presents a balanced view, highlighting both positive clinical results and financial stability alongside the inherent risks and challenges of drug development. The strong cash position and progress in clinical programs contribute to a moderately positive outlook.
Positives
- Positive topline data from Phase 2a obesity study of aleniglipron.
- Initiation of Phase 2b studies (ACCESS and ACCESS II) for aleniglipron.
- Advancement of ACCG-2671 to IND-enabling studies.
- Phase 1 clinical study initiated for LTSE-2578.
- Strong cash position to fund operations through at least 2027.
Negatives
- The company has incurred significant operating losses since its inception and expects to continue to incur significant losses for the foreseeable future.
- The company has no products approved for commercial sale and has not generated any revenue to date.
- Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain.
Risks
- Clinical trial delays or failures could increase costs and delay revenue generation.
- Adverse events or undesirable side effects of product candidates could lead to discontinuation of development programs or limitations on use.
- Reliance on third parties for manufacturing and clinical studies poses risks to supply and timelines.
- Competition from other pharmaceutical companies could impact market share and commercial success.
- Changes in regulations or healthcare laws could affect pricing and reimbursement of products.
- Cybersecurity threats could compromise sensitive data and disrupt operations.
- The company's operations in China are subject to political and economic risks.
- The company may be subject to U.S. Foreign Corrupt Practices Act (the FCPA), U.S. domestic bribery laws, and similar anti-corruption and anti-bribery laws of China and other countries in which it operates, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations.
Future Outlook
The company expects to continue to incur significant and increasing operating losses for the foreseeable future as it advances its product candidates through clinical trials and pursues regulatory approval.
Industry Context
The company operates in the competitive biopharmaceutical industry, facing competition from major pharmaceutical and biotechnology companies, academic institutions, and research institutions. The company is focused on developing oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need.
Comparison to Industry Standards
- The document mentions competitors such as Pfizer, Eli Lilly, Novo Nordisk, and Amgen, which are major players in the pharmaceutical industry.
- The document references approved GLP-1R peptides for diabetes and obesity marketed by Novo Nordisk and Eli Lilly, setting a benchmark for efficacy and safety.
- The document compares the company's approach to structure-based drug discovery with traditional high-throughput screening and rational design methods.
- The document compares LTSE-2578 to BMS's LPA1R antagonists in terms of histamine release inhibition.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Ramy Farid | June 25, 2024 | Ramy Farid was no longer a member of the board of directors |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Non-Employee Director Compensation Policy | The Non-Employee Director Compensation Policy was amended on January 21, 2025. | January 21, 2025 | The amendment may affect the compensation structure for non-employee directors. |
Related Party Transactions
- The company has existing collaboration agreements to use the results provided by Schrdingers software platform for its research purposes.
- Lhotse Bio, Inc. (Lhotse), the Companys wholly-owned subsidiary, entered into a Collaboration Agreement (the Lhotse-Schrdinger Agreement) with Schrdinger, which is one of the Companys shareholders, to discover and develop novel, orally bioavailable, small molecule inhibitors of lysophosphatidic acid 1 receptor (LPA1R).
- Aconcagua Bio, Inc. (Aconcagua), the Companys wholly-owned subsidiary, entered into a collaboration agreement (the Aconcagua-Schrdinger Agreement) with Schrdinger to discover and develop novel, small molecule modulators of a specific target.
- In May 2023, the Company entered into an Exchange Agreement with BVF, who in the aggregate held at the time of the transaction more than 5% of the Companys issued share capital, pursuant to which BVF delivered to the Company, a total of 7,410,518 ordinary shares of the Company, in exchange for the Companys delivery of 7,410,518 newly designated non-voting ordinary shares, par value $0.0001 per share.
Stakeholder Impact
- Shareholders may experience fluctuations in the value of their investments due to market volatility and company-specific factors.
- Employees may benefit from the company's growth and development, but also face risks related to job security and compensation.
- Patients may benefit from the development of new and effective treatments for chronic diseases.
- Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.
Next Steps
- Continue Phase 2b studies (ACCESS and ACCESS II) of aleniglipron.
- Initiate Phase 1 clinical study of ACCG-2671.
- Continue long term GLP-toxicology studies of ANPA-0073.
- Continue Phase 1 clinical study of LTSE-2578.
Key Dates
| Date | Description |
|---|---|
| December 1993 | The PRC Company Law was adopted |
| April 12, 1986 | General Principles of the Civil Law of the Peoples Republic of China (PRC Civil Law) promulgated |
| September 2, 1993 | The Peoples Republic of China Anti-Unfair Competition Law promulgated |
| October 31, 1993 | The Law of the Peoples Republic of China on the Protection of the Rights and Interests of Consumers was promulgated |
| January 1, 1995 | The Labor Law of the Peoples Republic of China, effective |
| February 11, 2002 | The Guiding Foreign Investment Direction was promulgated |
| November 1, 2002 | The Law of Manufacturing Safety of the Peoples Republic of China effective |
| January 1, 2004 | The Regulations on Work-related Injury Insurance, which became effective |
| March 2007 | The Enterprise Income Tax Law of the Peoples Republic of China (the EIT Law), which was promulgated |
| January 1, 2008 | The Employment Contract Law of the Peoples Republic of China, effective |
| January 1, 2008 | The Regulation on the Implementation of the EIT Law, effective |
| September 18, 2008 | The Implementing Regulations of the Employment Contract Law, effective |
| August 2008 | The Foreign Exchange Administration Regulations, most recently amended |
| April 22, 2009 | The Notice Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as Chinese Tax Resident Enterprises on the Basis of De Facto Management Bodies (SAT Circular 82), issued |
| July 1, 2010 | Under the Tort Law of the Peoples Republic of China (Tort Law), which became effective |
| March 1, 2011 | Pursuant to the Administrative Measures Governing the Production Quality of Pharmaceutical Products effective |
| July 1, 2011 | including the Social Insurance Law which became effective |
| February 2012 | SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies (the Stock Option Rules). |
| November 2012 | The Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment was promulgated by SAFE |
| May 2013 | SAFE promulgated the Circular on Printing and Distributing the Provisions on Foreign Exchange Administration over Domestic Direct Investment by Foreign Investors and the Supporting Documents |
| March 1, 2014 | Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales Industry, which became effective |
| July 2014 | the State Administration of Foreign Exchange (SAFE), issued SAFE Circular 37 |
| March 2015 | SAFE issued the Circular of the State Administration of Foreign Exchange on Reforming the Management Approach regarding the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises (SAFE Circular 19) |
| June 1, 2015 | SAFE Circular 19, which became effective and replaced SAFE Circular 142 |
| May 2015 | The Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment was amended |
| February 2015 | SAFE promulgated the Circular on Further Simplifying and Improving the Policies Concerning Foreign Exchange Control on Direct Investment (SAFE Circular 13), which took effect on June 1, 2015. |
| June 9, 2016 | SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account (SAFE Circular 16), effective |
| November 2016 | the Cyber Security Law, promulgated by the Standing Committee of the National Peoples Congress (SCNPC) |
| January 2017 | SAFE issued the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control |
| August 2017 | Domain names are protected under the Administrative Measures on the Internet Domain Names promulgated by the Ministry of Industry and Information Technology |
| October 2017 | Chinas drug regulatory system entered a new and significant period of reform |
| December 2017 | the PRC Anti-Unfair Competition Law, as amended |
| December 2017 | SAT Circular 82 |
| April 23, 2019 | the PRC Anti-Unfair Competition Law, as amended |
| March 2019 | The Foreign Investment Law of the Peoples Republic of China (the Foreign Investment Law) was promulgated by the National Peoples Congress (NPC) |
| December 2019 | the State Council issued the Regulations on Implementing the Foreign Investment Law |
| December 2019 | the MOFCOM and the SAMR issued the Measures for the Reporting of Foreign Investment Information |
| December 1, 2019 | The Peoples Republic of China Drug Administration Law (PRC Drug Administration Law), which became effective |
| January 2020 | After the Foreign Investment Law came into force, the Law on Wholly Foreign-Owned Enterprises of the Peoples Republic of China, the Law on Sino-foreign Equity Joint Ventures of the Peoples Republic of China and the Law on Sino-foreign Contractual Joint Ventures of the Peoples Republic of China have been repealed simultaneously. |
| January 2020 | After the Regulations on Implementing the Foreign Investment Law came into effect, the Regulation on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law, Provisional Regulations on the Duration of Sino-Foreign Equity Joint Venture Enterprise, the Regulations on Implementing the Wholly Foreign-Owned Enterprise Law and the Regulations on Implementing the Sino-Foreign Cooperative Joint Venture Enterprise Law have been repealed simultaneously. |
| January 2020 | After the Measures for the Reporting of Foreign Investment Information came into effect, the Interim Measures on the Administration of Filing for Establishment and Change of Foreign Investment Enterprises has been repealed simultaneously. |
| July 1, 2020 | The State Administration for Market Regulation (SAMR) has promulgated two key implementing regulations for the PRC Drug Administration Law: (i) the amended Administrative Measures for Drug Registration and (ii) the amended Measures on the Supervision and Administration of the Manufacture of Drugs. Both regulations took effect |
| May 2020 | The Civil Code of the Peoples Republic of China (PRC Civil Code), which was promulgated |
| July 1, 2020 | The rules on product liability in the PRC Civil Code remain consistent with the rules in the PRC Civil Law. |
| July 1, 2021 | Under the Tort Law of the Peoples Republic of China (Tort Law), which became effective |
| January 1, 2021 | The PRC Civil Code amalgamated and replaced the Tort Law effective |
| October 2020 | Lhotse, our wholly-owned subsidiary, entered into a collaboration agreement with Schrdinger (the Lhotse-Schrdinger Agreement) |
| October 2020 | the SCNPC promulgated the Biosecurity Law of the PRC |
| June 2021 | the PRC Patent Law, which was promulgated by the SCNPC in October 2020 and became effective |
| July 2021 | the NMPA and the CNIPA jointly published the Measures for Implementing an Early-Stage Resolution Mechanism for Pharmaceutical Patent Disputes (Tentative) (Measures on Patent Linkage) |
| July 6, 2021 | the General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued the Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law. |
| July 10, 2021 | the Cybersecurity Administration of China (the CAC) published a draft revision to the existing Cybersecurity Review Measures for public comment (the Revised Draft CAC Measures). |
| September 2021 | Chinas current Data Security Law took effect |
| November 14, 2021 | the CAC further published the Regulations on Network Data Security Management (Draft for Comment) for public comment. |
| November 1, 2021 | the Personal Information Protection Law of the PRC (PIPL) which became effective |
| December 2021 | the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered accounting firms headquartered in Mainland China and in Hong Kong. |
| December 2021 | the SEC adopted final amendments to its rules implementing the HFCA Act and established procedures to identify issuers and prohibit the trading of the securities of certain registrants as required by the HFCA Act. |
| January 4, 2022 | together with 12 other Chinese regulatory authorities, the CAC released the final version of the Revised Draft CAC Measures (the Revised CAC Measures), which came into effect on February 15, 2022. |
| February 4, 2022 | the U.S. House of Representatives passed the America Creating Opportunities for Manufacturing, Pre-Eminence in Technology, and Economic Strength Act of 2022, which contained, among other things, an identical provision. |
| July 22, 2022 | Executive Employment Agreement, by and between the registrant and Xichen Lin, dated |
| August 16, 2022 | the Inflation Reduction Act of 2022 (IRA) was signed into law |
| September 2022 | We completed our Phase 1 single ascending dose (SAD) study of aleniglipron |
| September 2022 | we completed a Phase 1 SAD and MAD study evaluating ANPA-0073 in healthy human volunteers, in which it was generally well tolerated. |
| November 1, 2022 | Employment Contract, by and between Shanghai ShouTi Biotechnology Co., Ltd. and Yingli Ma, dated |
| October 31, 2022 | Supplemental Agreement, by and among Shanghai Basecamp Biotechnology Co., Ltd., Shanghai ShouTi Biotechnology Co., Ltd. and Yingli Ma, dated |
| January 2023 | We initiated the Phase 1b multiple ascending dose (MAD) study of aleniglipron |
| January 2023 | we selected a development candidate, LTSE-2578 |
| February 3, 2023 | Our ADSs have been listed on the Nasdaq Global Market under the symbol GPCR since |
| March 2023 | We completed dosing in otherwise healthy overweight subjects in March 2023. |
| May 2023 | we submitted a protocol amendment to the FDA and initiated dosing of the Phase 2a proof-of-concept study in T2DM and obesity. |
| May 2023 | SAFE promulgated the Circular on Printing and Distributing the Provisions on Foreign Exchange Administration over Domestic Direct Investment by Foreign Investors and the Supporting Documents |
| June 2023 | Shanghai ShouTi entered into a lease agreement for approximately 22,500 square feet of office space in Shanghai, China, for its research and development operations office, which commenced in July 2023 and will expire on December 31, 2026. |
| June 2023 | StructureTx US entered into a sublease agreement for approximately 11,800 square feet of office space located in South San Francisco, California for its corporate headquarters. The lease commenced in July 2023 and will expire on August 31, 2027. |
| June 2023 | Shanghai ShouTi entered into another lease agreement for approximately 8,400 square feet of laboratory space located in Shanghai, China for its research and development activities. The lease commenced in December 2023 and will expire on January 31, 2027. |
| September 2023 | we reported topline data for the 28-day Phase 1b MAD study |
| September 2023 | we entered into a share purchase agreement with certain institutional investors |
| December 2023 | we reported clinically meaningful topline data from our Phase 2a T2DM cohort, interim results from our Phase 2a obesity cohort and topline data from a Japanese ethno-bridging study of aleniglipron. |
| October 2023 | we completed the Private Placement |
| November 2023 | Aconcagua, our wholly-owned subsidiary, entered into a collaboration agreement (the Aconcagua-Schrdinger Agreement) with Schrdinger |
| December 7, 2023 | an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. |
| December 8, 2023 | the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. |
| January 5, 2024 | the FDA approved Floridas Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. |
| January 2024 | Carmot Therapeutics acquired by Roche Group |
| June 2024 | we reported positive topline data from our Phase 2a obesity study |
| June 2024 | we initiated our first-in-human Phase 1 study of LTSE-2578. |
| June 2024 | we initiated a Phase 1 clinical study of LTSE-2578. |
| June 2024 | we issued and sold an aggregate of 10,427,017 ADSs in the Follow-On Offering. |
| July 2024 | we submitted an IND to the FDA to support the initiation of a Phase 2b study in chronic weight management |
| August 2024 | received FDA allowance |
| August 15, 2024 | HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations |
| September 24, 2024 | the State Council released the final version of the Draft Management Regulations (the Management Regulations), which came into effect on January 1, 2025. |
| September 26, 2024 | the Negative List), which was promulgated by the Ministry of Commerce of the Peoples Republic of China (MOFCOM), and National Development and Reform Commission (NDRC) |
| November 1, 2024 | took effect |
| October 2023 | Horizon Therapeutics acquired by Amgen |
| Q4 2024 | we initiated the Phase 2b ACCESS study |
| Q4 2024 | we initiated a randomized, double-blind, placebo-controlled dose-range finding Phase 2 study of aleniglipron, known as ACCESS II |
| February 2025 | we completed enrollment in the ACCESS and ACCESS II studies |
| Q4 2025 | we expect to report topline data from both studies |
| Q4 2025 | We expect to initiate Phase 1 clinical study of ACCG-2671 |
| January 1, 2025 | The Management Regulations, which came into effect |
| January 1, 2025 | The PRC Civil Code amalgamated and replaced the Tort Law effective |
| January 1, 2025 | the number of ordinary shares available for issuance under the 2023 Plan was increased by 6,874,398 shares as a result of the automatic increase provision in the 2023 Plan. |
| December 31, 2025 | extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.